Secukinumab as Biological Treatment for Psoriatic Arthritis in Real Clinical Practice.

Introduction: Clinical trials of secukinumab have demonstrated their efficacy and safety in psoriatic arthritis as biological first choice or after inadequate response to other biological treatments.

Objective: To analyze the efficacy and safety of secukinumab in peripheral psoriatic arthritis over 12 months in real clinical practice.

Material And Methods: Patients with active peripheral psoriatic arthritis who started treatment with secukinumab according to the technical specifications were included.

Epidemiological Characteristics and Adverse Events of Patients with Psoriatic Arthritis Undergoing Treatment with Biological Therapies in Galicia.

Unlabelled: Patients with severe forms of psoriatic arthritis (PsA) usually require treatment with biological agents. A greater knowledge of this subgroup of patients and their treatment enables better decision making in real clinical practice.

Methods: Longitudinal, multicentric observational study.